I agree that this site is using cookies. You can find further informations here.
X
Palmieri, Salvatore
407  results:
Search for persons X
?
1

Elotuzumab plus pomalidomide and dexamethasone in relapsed/..:

Martino, Enrica Antonia ; Palmieri, Salvatore ; Galli, Monica...
Hematological Oncology.  42 (2024)  4 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
2

Additional copies of 1q negatively impact the outcome of mu..:

D'Agostino, Mattia ; Rota-Scalabrini, Delia ; Belotti, Angelo...
Blood Cancer Journal.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
3

Elotuzumab plus pomalidomide and dexamethasone in relapsed/..:

Gentile, Massimo ; Vigna, Ernesto ; Palmieri, Salvatore...
Haematologica.  , 2023
Link: https://doi.org/10.3324/..
 
?
4

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal ..:

De Novellis, Danilo ; Fontana, Raffaele ; Palmieri, Salvatore...
Targeted Oncology.  18 (2023)  6 - p. 885-892 , 2023
Link: https://doi.org/10.1007/..
 
?
5

OAB-011: Predictors of unsustained negativity in minimal re..:

D'Agostino, Mattia ; Oliva, Stefania ; Rota-Scalabrini, Delia...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S6-S7 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Survival Risk Scores for Real-Life Relapsed/Refractory Mult..:

Morabito, Fortunato ; Zamagni, Elena ; Conticello, Concetta...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
7

Carfilzomib combined with lenalidomide and dexamethasone (K..:

Martino, Enrica Antonia ; Conticello, Concetta ; Zamagni, Elena...
Hematological Oncology.  40 (2022)  5 - p. 1009-1019 , 2022
Link: https://doi.org/10.1002/..
 
?
8

Efficacy and safety of belantamab-mafodotin in triple-refra..:

Iula, Rossella ; De Novellis, Danilo ; Trastulli, Fabio...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
9

Progressive multifocal leukoencephalopathy after immunochem..:

Borgo, Riccardo Maria ; Palmieri, Salvatore ; Cirillo, Mario...
Journal of the Neurological Sciences.  429 (2021)  - p. 118929 , 2021
Link: https://doi.org/10.1016/..
 
?
10

Adjusted comparison between elotuzumab and carfilzomib in c..:

Morabito, Fortunato ; Zamagni, Elena ; Conticello, Concetta...
European Journal of Haematology.  108 (2021)  3 - p. 178-189 , 2021
Link: https://doi.org/10.1111/..
 
?
11

KRD (carfilzomib and lenalidomide plus dexamethasone) for t..:

Palmieri, Salvatore ; Rocco, S. ; Vitagliano, O....
Annals of Hematology.  99 (2020)  12 - p. 2903-2909 , 2020
Link: https://doi.org/10.1007/..
 
?
12

MM-382: Bendamustine-Bortezomib-Dexamethasone (BVD) in Heav..:

Cerchione, Claudio ; Catalano, Lucio ; Nappi, Davide...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S310 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated..:

Cerchione, Claudio ; Catalano, Lucio ; Nappi, Davide...
Clinical Lymphoma Myeloma and Leukemia.  18 (2018)  - p. S254-S255 , 2018
Link: https://doi.org/10.1016/..
 
?
14

Early mortality in myeloma patients treated with first-gene..:

Bringhen, Sara ; Offidani, Massimo ; Palmieri, Salvatore...
Critical Reviews in Oncology/Hematology.  130 (2018)  - p. 27-35 , 2018
Link: https://doi.org/10.1016/..
 
?
15

Bendamustine-Bortezomib-Dexamethasone (BVD) in the Manageme..:

Cerchione, Claudio ; Catalano, Lucio ; Pareto, Anna Emanuele...
Clinical Lymphoma Myeloma and Leukemia.  17 (2017)  1 - p. e60-e61 , 2017
Link: https://doi.org/10.1016/..
 
1-15